ロード中...
Third-line therapy in the epidermal growth factor receptor mutation-positive advanced nonsmall-cell lung cancer
INTRODUCTION: The treatment of lung cancer is not defined in the third-line setting and remains an unanswered question. Erlotinib is the only drug approved in the third-line setting. With the introduction of effective first- and second-line therapies, more and more patients warrant an effective thir...
保存先:
| 出版年: | South Asian J Cancer |
|---|---|
| 主要な著者: | , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Wolters Kluwer - Medknow
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6956591/ https://ncbi.nlm.nih.gov/pubmed/31956622 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/sajc.sajc_28_19 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|